A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Part of paid clinical trials in Duarte, California.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT05444530
- Phase
- PHASE1
- Status
- Completed
Conditions
- Myeloproliferative Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- VAC85135 — BIOLOGICALParticipants will receive VAC85135 as IM injection.
- Ipilimumab — DRUGParticipants will receive Ipilimumab as IV infusion.
Study Details
The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).
Key Dates
- Start date
- Jul 21, 2022
- Status verified
- Jul 2025
- Primary completion
- Jun 24, 2025
- Completion
- Jun 24, 2025
Study Design
- Enrollment
- 14 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose EscalationParticipants with essential thrombocythemia (ET) and myelofibrosis (MF) will receive VAC85135 target dose intramuscular (IM) injection in the safety lead-in cohort (Cohort 0). Participants in subsequent cohorts will receive VAC85135 target dose IM injection along with ipilimumab intravenous (IV) infusion. Ipilimumab dose may be escalated based on dose limiting toxicity (DLT) observations.
- Experimental: Dose ExpansionParticipants with polycythemia vera (PV) or post-polycythemia vera myelofibrosis, ET and MF will receive VAC85135 target dose IM injection with ipilimumab IV infusion at the dose(s) determined by study evaluation team (SET).
Primary Outcome Measure
Number of Participants With Dose-limiting Toxicity (DLT) [ Time Frame: Baseline (Day 1) up to Day 78 ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | - |
| Moffitt Cancer Center | Tampa | Florida | 33612 | - |
| Cleveland Clinic | Cleveland | Ohio | 44195 | - |
| MD Anderson Cancer Center | Houston | Texas | 77030 | - |
Find similar trials in Duarte, CA
Related Studies
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsPHASE1 · Recruiting · Incyte Corporation · Duarte, California
- A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsPHASE1 · Recruiting · Incyte Corporation · Birmingham, Alabama
- A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsPHASE1 · Recruiting · Incyte Corporation · Phoenix, Arizona
- Study of INCA036978 in Participants With Myeloproliferative NeoplasmsPHASE1 · Recruiting · Incyte Corporation · Birmingham, Alabama